Introduction
============

Spinal anesthesia is a safe and reliable method of anesthesia for abdominal and lower limb surgery, with the advantages of rapid onset of action, economical and easy to administer, and a relatively low side effects rate and shorter post-anesthesia care unit stay.[@b1-dddt-11-3413],[@b2-dddt-11-3413] However, these advantages may be offset by the limited duration of action, or an increased likelihood of motor power recovery delay, thus delaying ambulation and prolonged hospital stay.[@b3-dddt-11-3413],[@b4-dddt-11-3413] In order to improve the quality of blockage and prolong the duration of analgesia, and reduce the required dose of local anesthetics, thereby reducing the incidence of side effects caused by the use of high-dose local anesthetics, such as late and severe bradycardias, hypotension, nausea, and vomiting, appropriate adjuvants are commonly used for intrathecal local anesthetics.[@b5-dddt-11-3413],[@b6-dddt-11-3413]

It has been found that many drugs, such as opioids (morphine, fentanyl, and sufentanil), α~2~ adrenergic agonists (dexmedetomidine \[Dex\] and clonidine), magnesium sulfate, neostigmine, ketamine, and midazolam, can be used as adjuvants for intrathecal local anesthetics to improve the quality of spinal anesthesia.[@b7-dddt-11-3413] However, the opioids and α~2~ adrenergic agonists are more commonly used as adjuvants in clinical practice. During the intrathecal or epidural administration, fentanyl has a more rapid onset and shorter duration of action than morphine, which has become one of the most commonly used neuraxial opioids. Dex, a selective α~2~ adrenergic receptor agonist, has been shown to be a better adjuvant of local anesthetics for neuraxial blocks,[@b8-dddt-11-3413]--[@b10-dddt-11-3413] although clonidine is the first clinically used intrathecal α~2~-adrenoreceptor agonist.[@b11-dddt-11-3413]

There is limited research of multi-center large sample randomized controlled trials (RCTs) to evaluate the advantages or disadvantages between Dex and fentanyl as local anesthetics adjuvants in spinal anesthesia. Moreover, some of their results were disputable. Therefore, the present meta-analysis was performed to confirm their conclusions using a large sample size.

Methods
=======

Searching strategy
------------------

Two researchers searched PUBMED, EMBASE, Cochrane library, and CBM independently. The mesh and keywords used for the searches included: "Dex", "Fentanyl", "Anesthesia, Spinal", "Injections, Spinal", "Bupivacaine", "ropivacaine", and "Randomized controlled trial". The latest search was done on May 20, 2017. Furthermore, the investigators scanned references of these articles to prevent missing articles.

Study inclusion criteria
------------------------

The trials included in our meta-analysis: adult patients (aged ≥18 years) undergoing spinal anesthesia were randomly assigned to groups (at least two groups), including Dex alone as an adjuvant to local anesthetics and fentanyl alone as an adjuvant to local anesthetics. Children, diabetics, drug addicts, and those with contraindications to spinal block were excluded.

Data extraction
---------------

### Data extraction and study characteristics

Two reviewers independently selected eligible studies, using a standard data collection table to extract data and record the trial characteristics. For each study, the following information was collected: the first author's name, date of publication, number of patients, peak sensory block level, types of surgery, the drugs and total volume for spinal anesthesia ([Table 1](#t1-dddt-11-3413){ref-type="table"}). The onset of sensory block: the time between intrathecal injection to the T12 or higher dermatome.The onset of motor block: the time between intrathecal injection to the modified Bromage score (modified Bromage scale: 0= no motor loss, 1= inability to flex the hip, 2= inability to flex the knee, 3= inability to flex the ankle)[@b12-dddt-11-3413] of 1 or higher score.Time to peak sensory level: the time to the highest dermatomal level of sensory block.Duration of stable sensory block: the time of regression to T10 or two dermatome segments from the maximum sensory block level.Duration of sensory block: the time of regression to S1 from the maximum sensory block level.Duration of motor block: the time of regression to modified Bromage score of 0.Pain free period: the time from intrathecal injection to the first time of complaint about pain or rescue analgesia.Side effects: the occurrence of nausea, vomiting, shivering or respiratory depression.

The level of sensory block was tested bilaterally along the mid-clavicular lines by pin prick, while the motor block was assessed according to the modified Bromage scale.

Assessment of risk of bias
--------------------------

Two reviewers independently read and evaluated the methodological validity of all eligible studies using Cochrane Handbook v5.0.2. Any discrepancies were resolved through joint discussion, if necessary, a third researcher assisted in the decision. The following information was evaluated: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, other bias, and each of them was graded as "high risk of bias", "uncertain risk of bias", "low risk of bias".

Statistical analysis
--------------------

Quantitative analyses of all included RCTs were performed using Review Manager Software (version 5.3; Cochrane Collaboration, Copenhagen, Denmark). For dichotomous data, risk ratios with 95% confidence intervals (CIs) were computed using the Mantel-Haenszel method. When the measuring methods or indicator units used for the same interventions were different, or the mean difference (MD) between the different studies was large, the standardized mean difference (SMD) with 95% CIs were calculated using the inverse variance method, otherwise the MD with 95% CIs were calculated using the same method for continuous data. Meta-analysis was not performed for studies which did not report mean and SD or standard error of the mean (SEM). For heterogeneity analyses: data that were not significantly homogeneous (*I*^2^\<50%) were analyzed with a fixed-effect model, otherwise, a random effect model was selected. When there was significant heterogeneity, we looked for possible causes of heterogeneity and performed subgroup analysis and sensitivity analysis to eliminate heterogeneity as much as possible.

Results
=======

Characteristics and risk of bias of eligible trials
---------------------------------------------------

The flow chart of our study is shown in [Figure 1](#f1-dddt-11-3413){ref-type="fig"}. A total of nine RCTs were identified, involving 639 patients (320 received Dex and 319 fentanyl). The results of the included studies in the meta-analysis were shown in [Tables 2](#t2-dddt-11-3413){ref-type="table"} and [3](#t3-dddt-11-3413){ref-type="table"}. Eight studies[@b12-dddt-11-3413]--[@b19-dddt-11-3413] used bupivacaine (two of these were low-dose bupivacaine) and one study[@b6-dddt-11-3413] used ropivacaine for spinal anesthesia. In these studies, five compared Dex with fentanyl,[@b6-dddt-11-3413],[@b12-dddt-11-3413],[@b13-dddt-11-3413],[@b18-dddt-11-3413],[@b19-dddt-11-3413] and the other two compared Dex with fentanyl and saline,[@b16-dddt-11-3413],[@b17-dddt-11-3413] the remaining two compared Dex with fentanyl and clonidine as well as saline.[@b14-dddt-11-3413],[@b15-dddt-11-3413] This meta-analysis only compares Dex with fentanyl, so we neglected clonidine and saline. The two reviewers were perfectly consistent on the risk of bias assessment, which showed that overall study quality was moderate. The risk-of-bias plot was created using the Review Manager 5.3 software, as shown in [Figure 2](#f2-dddt-11-3413){ref-type="fig"}.

The onset of sensory block
--------------------------

Six RCTs[@b12-dddt-11-3413],[@b14-dddt-11-3413],[@b15-dddt-11-3413],[@b17-dddt-11-3413]--[@b19-dddt-11-3413] reported the onset of sensory block, but two of them described only the mean of the index without the SD, and the meta-analysis contained only the remaining four ([Figure 3](#f3-dddt-11-3413){ref-type="fig"}). The result of meta-analysis showed that there was no significant difference of the onset of sensory block between the two groups (MD =−0.49; 95% CI \[−1.12, 0.14\], *P*\>0.05, *I*^2^=60%).

The onset of motor block
------------------------

Eight studies[@b6-dddt-11-3413],[@b12-dddt-11-3413]--[@b14-dddt-11-3413],[@b16-dddt-11-3413]--[@b19-dddt-11-3413] compared the onset time of motor block of Dex and fentanyl as local anesthetic adjuvants for intrathecal injection. There was significant heterogeneity among the results (*I*^2^=80%), and the random effect model was used for meta-analysis ([Figure 4A](#f4-dddt-11-3413){ref-type="fig"}). The result showed that there was no significant difference between the two groups (MD =−0.28; 95% CI \[−1.34, 0.79\], *P*\>0.05, *I*^2^=80%).

### Sensitivity analysis

There was a study[@b12-dddt-11-3413] of spinal anesthesia with a low dose of local anesthetic (bupivacaine only 4 mg), which may have resulted in heterogeneity among studies, after removing the study there was no heterogeneity between the remaining studies (*I*^2^=0). Meta-analysis was performed using the fixed effect model ([Figure 4B](#f4-dddt-11-3413){ref-type="fig"}). The result showed that there was still no significant difference between the two groups (MD =0.3; 95% CI \[−0.15, 0.75\], *P*\>0.05, *I*^2^=0).

Time to peak sensory level
--------------------------

All of the included studies reported the time to peak sensory level, with 320 patients in the Dex group and 319 patients in the fentanyl group. There was moderate heterogeneity among the results (*I*^2^=62%), and the random effect model was used for meta-analysis ([Figure 5](#f5-dddt-11-3413){ref-type="fig"}). The results showed no significant difference between the two groups (MD =0.1; 95% CI \[−0.59, 0.79\], *P*\>0.05, *I*^2^=62%).

Duration of stable sensory block
--------------------------------

Six RCTs[@b13-dddt-11-3413]--[@b16-dddt-11-3413],[@b18-dddt-11-3413],[@b19-dddt-11-3413] reported the indicator of duration of stable sensory block, with high heterogeneity among the results (*I*^2^=97%), and the random effect model was used for meta-analysis ([Figure 6A](#f6-dddt-11-3413){ref-type="fig"}). The results showed that the duration of stable sensory block of the Dex group was significantly higher than the fentanyl group, the difference was statistically significant (MD =27.12; 95% CI \[9.89, 44.34\], *P*\<0.01, *I*^2^=97%).

### Sensitivity analysis

Two of the six studies included may have led to heterogeneity among studies. One study[@b15-dddt-11-3413] used low-dose local anesthetic (4 mg bupivacaine) in spinal anesthesia and another[@b16-dddt-11-3413] had low quality, after removing both studies there was no heterogeneity between the remaining studies (*I*^2^=0). The result of meta-analysis ([Figure 6B](#f6-dddt-11-3413){ref-type="fig"}), using a fixed effect model, showed that the difference was still statistically significant (MD =28.98; 95% CI \[24.01, 33.96\], *P*\<0.01, *I*^2^=0).

Duration of sensory and motor block
-----------------------------------

Whatever the local anesthetics dose for spinal anesthesia \>10 mg (sensory: SMD =14.93; 95% CI \[10.80, 19.07\], *P*\<0.01, *I*^2^=76%, motor: SMD =10.82; 95% CI \[1.54, 20.11\], *P*\<0.05, *I*^2^=98%) or the local anesthetics dose for spinal anesthesia was ≤10 mg (sensory: SMD =1.01; 95% CI \[0.70, 1.31\] *P*\<0.01, *I*^2^=39%, motor: SMD =0.77; 95% CI \[0.06, 1.48\], *P*\<0.05, *I*^2^=89%) or pooled (sensory: SMD =3.81; 95% CI \[2.35, 5.27\] *P*\<0.01, *I*^2^=97%, motor: SMD =3.64; 95% CI \[2.19, 5.08\], *P*\<0.01, *I*^2^=97%), Dex as an adjuvant of local anesthetics significantly prolonged the duration of sensory and motor block compared with fentanyl. But there was significant heterogeneity in the duration of sensory (*I*^2^=76%) and motor (*I*^2^=98%) block when the local anesthetics dose for spinal anesthesia was \>10 mg, while the heterogeneity was not obvious in sensory block (*I*^2^=39%) but still significant in motor block (*I*^2^=89%) when the local anesthetics dose for spinal anesthesia was ≤10 mg, however, the heterogeneity of both was significant when pooled (sensory: *I*^2^=97%, motor: *I*^2^=97%; [Figures 7](#f7-dddt-11-3413){ref-type="fig"} and [8](#f8-dddt-11-3413){ref-type="fig"}).

Pain free period
----------------

A total of seven studies[@b12-dddt-11-3413]--[@b16-dddt-11-3413],[@b18-dddt-11-3413],[@b19-dddt-11-3413] were included. The result of meta-analysis, using a random effect model, showed that the pain free period of the Dex group was significantly longer than the fentanyl group, and the difference was statistically significant, but there was high heterogeneity (SMD =2.98; 95% CI \[1.69, 4.27\], *P*\<0.01, *I*^2^=96%; [Figure 9A](#f9-dddt-11-3413){ref-type="fig"}).

### Sensitivity analysis

One[@b19-dddt-11-3413] of the seven studies defined the index of pain free period from spinal injection to the time of first complaint about pain, while the remaining studies used the time from intrathecal injection to the first time rescue analgesia; and the other two studies[@b12-dddt-11-3413],[@b15-dddt-11-3413] used low-dose local anesthetic (4 mg bupivacaine) in spinal anesthesia. After removing the three studies, the heterogeneity of the remaining studies was significantly reduced (*I*^2^=27%), and the fixed effect model was used for meta-analysis. The results showed that the difference was still statistically significant (SMD =3.47; 95% CI \[3.04, 3.90\], *P*\<0.01, *I*^2^=27%; [Figure 9B](#f9-dddt-11-3413){ref-type="fig"}).

Hypotension and bradycardia
---------------------------

Eight studies[@b6-dddt-11-3413],[@b12-dddt-11-3413]--[@b14-dddt-11-3413],[@b16-dddt-11-3413]--[@b19-dddt-11-3413] described the incidence of hypotension and bradycardia in Dex and fentanyl as local anesthetic adjuvants for intrathecal injection. There were 245 patients in the Dex group (19 with hypotension and 20 with bradycardia) and 244 patients in the fentanyl group (25 with hypotension and eleven with bradycardia). There was no heterogeneity among the results (*I*^2^=0%), using the fixed effect model for meta-analysis ([Figure 10](#f10-dddt-11-3413){ref-type="fig"}). The results showed the difference was not statistically significant (hypotension: RR =0.76; 95% CI \[0.44, 1.32\], *P*\>0.05, *I*^2^=0%; bradycardia: RR =1.72; 95% CI \[0.88, 3.36\], *P*\>0.05, *I*^2^=0%).

Pruritus
--------

There were eight studies[@b6-dddt-11-3413],[@b12-dddt-11-3413]--[@b14-dddt-11-3413],[@b16-dddt-11-3413]--[@b19-dddt-11-3413] reporting the incidence of pruritus, and no heterogeneity among the studies (*I*^2^=0%). The results of the meta-analysis, using the fixed effect model, showed that the incidence of pruritus in the fentanyl group was significantly higher than the Dex group, and the difference was statistically significant (RR =0.15; 95% CI \[0.06, 0.39\], *P*\<0.01, *I*^2^=0%, [Figure 11](#f11-dddt-11-3413){ref-type="fig"}).

The side effects
----------------

Eight studies[@b6-dddt-11-3413],[@b12-dddt-11-3413]--[@b14-dddt-11-3413],[@b16-dddt-11-3413]--[@b19-dddt-11-3413] recorded the side effects, and there was no heterogeneity among the studies (*I*^2^=0%). The side effects included nausea, vomiting, shivering, and respiratory depression. The meta-analysis result of the incidence of the side effects between Dex and fentanyl group was not statistically significant (RR =0.75; 95% CI \[0.49, 1.14\], *P*\>0.05, *I*^2^=0%, [Figure 12](#f12-dddt-11-3413){ref-type="fig"}).

Discussion
==========

Spinal anesthesia is a common technique for lower abdomen and lower limb surgery, but the use of local anesthetics alone may produce unwanted side effects such as prolonged motor and autonomic block, limited duration of action, besides, excessive local anesthetics can cause cardiac toxicity and central nervous system side effects.[@b7-dddt-11-3413] For these reasons, local anesthetics combined with other drugs, to utilize their synergistic analgesia and to reduce the dose of local anesthetics, has become a new option for anesthesiologists. Of course, adjuvants are not necessary for spinal anesthesia and additional medical expenses of adjuvants should also be considered, moreover, adjuvants may themselves cause side effects, eg, higher doses of opioids may cause pruritus and Dex may cause bradycardia.

Opioids as an adjuvant has been the most commonly used to reduce the dose of intrathecal local anesthetics and improve the block quality, however, many of the adverse effects associated with the use of opioids plague everyone, such as urinary retention, pruritus, nausea and vomiting, and respiratory depression.[@b20-dddt-11-3413]--[@b22-dddt-11-3413] It has been found that Dex prolongs the postoperative analgesia of local anesthetics with less side effects, and is a very promising adjuvant to improve the quality of spinal anesthesia.[@b23-dddt-11-3413]--[@b26-dddt-11-3413] This meta-analysis was designed to evaluate the efficacy and characteristics of Dex and fentanyl as adjuvants to local anesthetics during spinal anesthesia.

In this meta-analysis, Dex significantly prolonged the duration of sensory and motor block compared with fentanyl, and had a longer pain free period and less postoperative analgesic requirements. But there was a high level of heterogeneity among these outcomes, which may be related to the following: 1) the dose and type of local anesthetics for intrathecal injection were different among studies included, meanwhile the dose of Dex and fentanyl was also different; 2) the evaluation criteria for the indicator of pain free period was different between studies -- in one study it was the time from intrathecal injection to time patient first complained of pain postoperatively -- while in others the first rescue analgesia was used; 3) unit of measurement for indicating pain free period was different, Nayagam et al used hours,[@b15-dddt-11-3413] while the remaining studies used minutes; 4) the type and duration of surgeries were different. Our results showed that the incidence of pruritus in the Dex group was significantly lower than in the fentanyl group, but there was no significant difference in the incidence of other side effects (nausea, vomiting, shivering, or respiratory depression).

Coombs et al[@b27-dddt-11-3413] first introduced the analgesic properties of α~2~ adrenergic receptor agonists during intrathecal injection. Subsequent studies have shown that the abirritation of intrathecal α~2~-adrenoreceptor agonists is mainly achieved by inhibiting the release of C-fiber transmitters and substance P, and hyperpolarizing post-synaptic dorsal horn neurons,[@b20-dddt-11-3413],[@b28-dddt-11-3413],[@b29-dddt-11-3413] and the analgesic effect has a good correlation with their binding affinity to the spinal α~2~ adrenergic receptors.[@b30-dddt-11-3413] Therefore, Dex as a highly selective α~2~-adrenoreceptor agonist (α~2~/α~1~ 1,600:1), has greater advantages than clonidine in intrathecal injection for analgesia.

The greatest concern about the intrathecal application of Dex is its neurotoxicity. It managed to cause moderate to severe demyelination of white matter when it was administered by epidural route at a dose of up to 6.1 µg·kg^−1^ in rabbits.[@b31-dddt-11-3413] However, in an experiment with sheep, Dex (2.5--100 µg) intrathecal injection did not cause neurological deficits.[@b32-dddt-11-3413] In the systematic review by Abdallah and Brull,[@b2-dddt-11-3413] doses of Dex up to 0.2 µg·kg^−1^ for intrathecal and 1 µg·kg^−1^ for peripheral administration did not produce any neurotoxic manifestations, of course, the conclusion was based on isolated small animal data. Three of the studies reported the results of neurological deficits secondary to spinal anesthesia: no patients had neurological impairment within 1 week postoperatively in Gupta et al's study;[@b16-dddt-11-3413] during 48-hour postoperative follow-up, there was a case of post-dural puncture headache in the fentanyl group, and a case of transient nerve syndrome in the Dex group, but both were transient, not severe, and did not need additional treatment;[@b6-dddt-11-3413] Al-Ghanem et al[@b17-dddt-11-3413] reported two patients with postdural puncture headache, but they were in the fentanyl group. At present, most of the data have shown that Dex intrathecal application did not appear very severe neurotoxicity performance on human in the short term,[@b33-dddt-11-3413],[@b34-dddt-11-3413] but the data of long-term neurotoxicity performance are absent.

There are some limitations in our meta-analysis. First, it is possible we have missed some studies that satisfied the inclusion criteria, and some studies had to be excluded as the full text was unavailable. Second, there was significant heterogeneity regarding the duration of sensory and motor block, and pain free period, as there were different intrathecal drugs (bupivacaine, ropivacaine), different doses of drugs, and different evaluation criteria and types of surgery. Third, Dex intrathecal application caused delayed recovery of motor power whether there is practical clinical significance, such as venous thrombosis of lower limbs, prolonged hospitalization, and whether Dex combined with low-dose local anesthetics can eliminate these drawbacks, we did not analyze due to lack of research data. However, these questions are very meaningful research points for the future.

In summary, when compared to fentanyl, we found that Dex, as adjuvant to local anesthetics for intrathecal injection, can statistically significantly prolong the duration of sensory and motor block, as well as the pain free period, meanwhile significantly reducing the incidence of pruritus without increasing the risk of hypotension and bradycardia.
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![The risk of bias assessment of the included studies.\
**Note:** There were no high risk of bias found in these studies.](dddt-11-3413Fig2){#f2-dddt-11-3413}

![Forest plot for the onset of sensory block in minutes.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig3){#f3-dddt-11-3413}

![Forest plot for the onset of motor block in minutes (**A**), forest plot for sensitivity analysis of the onset of motor block in minutes (**B**).\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig4){#f4-dddt-11-3413}

![Forest plot for the time to peak sensory level.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig5){#f5-dddt-11-3413}

![Forest plot for duration of stable sensory block in minutes (**A**), forest plot for the sensitivity analysis of duration of stable sensory block in minutes (**B**).\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig6){#f6-dddt-11-3413}

![Forest plot for the subgroup analysis of duration of sensory block in minutes.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig7){#f7-dddt-11-3413}

![Forest plot for the subgroup analysis of duration of motor block in minutes.\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig8){#f8-dddt-11-3413}

![Forest plot for pain free period in minutes (**A**), forest plot for the sensitivity analysis of pain free period in minutes (**B**).\
**Abbreviations:** SD, standard deviation; CI, confidence interval; IV, inverse variance.](dddt-11-3413Fig9){#f9-dddt-11-3413}

![Forest plot comparing the incidence of hypotension and bradycardia.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](dddt-11-3413Fig10){#f10-dddt-11-3413}

![Forest plot comparing the incidence of pruritus.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](dddt-11-3413Fig11){#f11-dddt-11-3413}

![Forest plot comparing the incidence of side effects.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel.](dddt-11-3413Fig12){#f12-dddt-11-3413}

###### 

Characteristics of the included studies

  Study                                     Year   Application (µg)   Sample size   Local anesthetics (mg)   Total volume (mL)   PSBL (D/F)                                                            Operation
  ----------------------------------------- ------ ------------------ ------------- ------------------------ ------------------- --------------------------------------------------------------------- ---------------------------
  Qi et al[@b6-dddt-11-3413]                2016   NS/D5/F15          36/36/36      Rop 7.5                  2                   T 9.64±2.31/T9.86±2.03[\*](#tfn1-dddt-11-3413){ref-type="table-fn"}   Hysteroscopic procedures
  Basuni and Ahmed Ezz[@b12-dddt-11-3413]   2014   D3/F10             30/30         Bup 4                    3                   T8 (6--11)/T8 (5--11)[\#](#tfn2-dddt-11-3413){ref-type="table-fn"}    Knee arthroscopy
  Suresh and Prasad[@b13-dddt-11-3413]      2016   D5/F25             30/30         Bup 12.5                 3                   T6 (4--8)/T8 (6--10)[\#](#tfn2-dddt-11-3413){ref-type="table-fn"}     Lower abdominal surgeries
  Li et al[@b14-dddt-11-3413]               2015   NS/D10/C75/F15     21/21/21/21   Bup 10                   4                   T4 (44%)/T4 (42%)[a](#tfn3-dddt-11-3413){ref-type="table-fn"}         Cesarean section
  Nayagam et al[@b15-dddt-11-3413]          2014   D5/F25             75/75         Bup 4                    1.6                 T4 (4%)/T6 (9%)[a](#tfn3-dddt-11-3413){ref-type="table-fn"}           Lower abdominal surgeries
  Gupta et al[@b16-dddt-11-3413]            2011   D5/F25             30/30         Bup 12.5                 3                   T5 (4--8)/T6 (4--7)[\#](#tfn2-dddt-11-3413){ref-type="table-fn"}      Lower abdominal surgeries
  Al-Ghanem et al[@b17-dddt-11-3413]        2009   D5/F25             38/38         Bup 10                   2.5                 T6 (4--9)/T6 (3--8)[\#](#tfn2-dddt-11-3413){ref-type="table-fn"}      Gynecological operation
  Sun et al[@b18-dddt-11-3413]              2015   NS/F25/D10         30/30/30      Bup 10                   3                   T4 (44%)/T4 (40%)[a](#tfn3-dddt-11-3413){ref-type="table-fn"}         Cesarean section
  Mahendru et al[@b19-dddt-11-3413]         2013   NS/D5/C30/F25      30/30/30/30   Bup 12.5                 3                   T6 (26.7%)/T6 (13.3%)[a](#tfn3-dddt-11-3413){ref-type="table-fn"}     Lower limb surgery

**Notes:**

Values are mean ± standard deviation;

data presented as median (range);

highest sensory block level (%).

**Abbreviations:** NS, saline; D, dexmedetomidine; F, fentanyl; Rop, ropivacaine; Bup, bupivacaine; C, clonidine; PSBL, peak sensory block level; T, thoracic level.

###### 

The summary of results from individual studies

  Study                                     Year   Application   The onset of sensory block (min)[\*](#tfn5-dddt-11-3413){ref-type="table-fn"}   The onset of motor block (min)[\*](#tfn5-dddt-11-3413){ref-type="table-fn"}   Time to peak sensory level (min)[\*](#tfn5-dddt-11-3413){ref-type="table-fn"}   Duration of stable sensory block (min)[\*](#tfn5-dddt-11-3413){ref-type="table-fn"}   Duration of sensory block (min)[\*](#tfn5-dddt-11-3413){ref-type="table-fn"}
  ----------------------------------------- ------ ------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Qi et al[@b6-dddt-11-3413]                2016   D                                                                                             20.42±5.25                                                                    10.78±5.94                                                                                                                                                            191.25±40.24
                                            F                    18.94±4.45                                                                      9.19±5.61                                                                                                                                                     149.86±37.46                                                                          
  Basuni and Ahmed Ezz[@b12-dddt-11-3413]   2014   D             3.9±1.2                                                                         14.1±2.3                                                                      10.7±2.3                                                                                                                                                              73.9±13.9
                                            F      5.1±1.5       18.9±4.1                                                                        13.8±4.4                                                                                                                                                      64.9±11.3                                                                             
  Suresh and Prasad[@b13-dddt-11-3413]      2016   D                                                                                             5.71±1.369                                                                    6.37±1.06                                                                       110.33±11.54                                                                          453.67±23.26
                                            F                    5.41±1.69                                                                       6.52±1.90                                                                     81.50±15.6                                                                      180.70±18                                                                             
  Li et al[@b14-dddt-11-3413]               2015   D                                                                                             7.2±2.25                                                                      8.10±3.55                                                                       155.9±19.85                                                                           225.73±47.88
                                            F                    7.3±2.80                                                                        8.47±2.18                                                                     127.71±18.36                                                                    181.0±35.43                                                                           
  Nayagam et al[@b15-dddt-11-3413]          2014   D             4.9±0.92                                                                                                                                                      12.9±3.131                                                                      61.79±5.86                                                                            
                                            F      5.1±0.82                                                                                      11.8±2.156                                                                    60.24±4.89                                                                                                                                                            
  Gupta et al[@b16-dddt-11-3413]            2011   D                                                                                             11.6±1.8                                                                      12.3±1.8                                                                        120±22.2                                                                              476±20
                                            F                    11.2±1.3                                                                        12.1±1.7                                                                      76±20.3                                                                         187±12.3                                                                              
  Al-Ghanem et al[@b17-dddt-11-3413]        2009   D             7.5±7.4                                                                         14.4±6.7                                                                      19.34±2.87                                                                                                                                                            274.8±73.4
                                            F      7.4±3.3       14.3±5.7                                                                        18.39±2.46                                                                                                                                                    179.5±47.4                                                                            
  Sun et al[@b18-dddt-11-3413]              2015   D                                                                                             7.1±2.25                                                                      8.10±3.55                                                                       152.9±39.62                                                                           211.73±51.88
                                            F                    7.4±2.80                                                                        8.47±2.18                                                                     117.71±21.36                                                                    179.0±38.83                                                                           
  Mahendru et al[@b19-dddt-11-3413]         2013   D             8.3±2.4                                                                         9.7±3.2                                                                       10.3±3.3                                                                        146.7±20.5                                                                            
                                            F      8.6±1.5       9.0±3.0                                                                         9.6±2.9                                                                       119.5±22.7                                                                                                                                                            

**Note:**

Values are mean ± standard deviation.

**Abbreviations:** D, dexmedetomidine; F, fentanyl.

###### 

The summary of results from individual studies

  Study                                     Year   Application    Duration of motor block (min)[\*](#tfn7-dddt-11-3413){ref-type="table-fn"}   Pain free period (min)[\*](#tfn7-dddt-11-3413){ref-type="table-fn"}   Hypotension/bradycardia[\#](#tfn8-dddt-11-3413){ref-type="table-fn"}   Pruritus[\#](#tfn8-dddt-11-3413){ref-type="table-fn"}   Side effects[\#](#tfn8-dddt-11-3413){ref-type="table-fn"}
  ----------------------------------------- ------ -------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------
  Qi et al[@b6-dddt-11-3413]                2016   D              146.31±40.72                                                                                                                                       0/3                                                                    0                                                       15
                                            F      80.28±41.18                                                                                 0/2                                                                   13                                                                     12                                                      
  Basuni and Ahmed Ezz[@b12-dddt-11-3413]   2014   D              73.3±8.5                                                                     126.6±12.9                                                            0/1                                                                    0                                                       0
                                            F      64.2±11.9      70.2±8.4                                                                     2/0                                                                   0                                                                      0                                                       
  Suresh and Prasad[@b13-dddt-11-3413]      2016   D              407.53±18.91                                                                 231.93±17.83                                                          5/9                                                                    0                                                       6
                                            F      149.37±12.00   160.13±15                                                                    5/2                                                                   3                                                                      7                                                       
  Li et al[@b14-dddt-11-3413]               2015   D              128.55±28.90                                                                 360.52±29.57                                                          3/1                                                                    1                                                       2
                                            F      130.65±29.87   275.72±25.16                                                                 3/2                                                                   1                                                                      4                                                       
  Nayagam et al[@b15-dddt-11-3413]          2014   D                                                                                           8.20±2.78 (h)                                                                                                                                                                                        
                                            F                     6.64±2.32 (h)                                                                                                                                                                                                                                                                     
  Gupta et al[@b16-dddt-11-3413]            2011   D              421±21                                                                       251.7±30.69                                                           3/1                                                                    0                                                       1
                                            F      149.3±18.2     168.96±15.96                                                                 2/0                                                                   1                                                                      3                                                       
  Al-Ghanem et al[@b17-dddt-11-3413]        2009   D              240±64                                                                                                                                             4/2                                                                    0                                                       2
                                            F      155±46                                                                                      9/3                                                                   5                                                                      4                                                       
  Sun et al[@b18-dddt-11-3413]              2015   D              128.55±28.90                                                                 352.45±26.17                                                          4/2                                                                    1                                                       3
                                            F      130.65±29.87   265.72±25.16                                                                 4/2                                                                   1                                                                      8                                                       
  Mahendru et al[@b19-dddt-11-3413]         2013   D              273.3±24.6                                                                   295.5±44.3                                                            0/1                                                                    0                                                       0
                                            F      196.0±26.8     235.5±38.3                                                                   0/0                                                                   4                                                                      1                                                       

**Notes:**

Values are mean ± standard deviation;

values are numbers.

**Abbreviations:** D, dexmedetomidine; F, fentanyl.
